Cargando…
Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial
BACKGROUND: Fatigue is a common symptom in stroke survivors for which there is currently no proven therapy. Modafinil is a wakefulness-promoting agent with established benefits in other disease models. We aim to test if modafinil will improve patient’s self-reported fatigue scores when compared to p...
Autores principales: | Lillicrap, Thomas, Krishnamurthy, Venkatesh, Attia, John, Nilsson, Michael, Levi, Christopher R., Parsons, Mark W., Bivard, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989372/ https://www.ncbi.nlm.nih.gov/pubmed/27534856 http://dx.doi.org/10.1186/s13063-016-1537-4 |
Ejemplares similares
-
MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
por: Bivard, Andrew, et al.
Publicado: (2017) -
Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
por: Lillicrap, Thomas P., et al.
Publicado: (2018) -
Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue
por: Visser, Milanka M., et al.
Publicado: (2019) -
Does modafinil enhance activity of patients with myotonic dystrophy?: A double-blind placebo-controlled crossover study
por: Wintzen, A.R., et al.
Publicado: (2007) -
Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease
por: Gorman, Gráinne S., et al.
Publicado: (2015)